4420 Research Article Disabled-2 is a novel ␣IIb-integrin-binding protein that negatively regulates platelet-fibrinogen interactions and platelet aggregation Chien-Ling Huang1, Ju-Chien Cheng2, Arnold Stern3, Jer-Tsong Hsieh4, Chang-Hui Liao5,* and Ching-Ping Tseng1,6,* 1Graduate Institute of Basic Medical Sciences, Chang Gung University, Taoyuan 333, Taiwan, Republic of China 2School of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404, Taiwan, Republic of China 3Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA 4Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA 5Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan, Republic of China 6Graduate Institute of Medical Biotechnology, Chang Gung University, 259 Wen-Hwa 1st Road, Kwei-Shen, Taoyuan 333, Taiwan, Republic of China *Authors for correspondence (e-mail:
[email protected];
[email protected]) Accepted 27 July 2006 Journal of Cell Science 119, 4420-4430 Published by The Company of Biologists 2006 doi:10.1242/jcs.03195 Summary Platelet aggregation plays a pivotal role in the haemostatic acid residues 64-66) and the ␣IIb-integrin–fibrinogen- process and is involved in the pathological counterpart of binding region (amino acid residues 171-464) are important arterial thrombosis. We have shown that the adapter for the DAB2-platelet interactions. Such interactions protein disabled-2 (DAB2) is expressed abundantly in compete for the binding of ␣IIb integrin with fibrinogen platelets. In this study, DAB2 was found to distribute in the and provide a mechanism for DAB2 to inhibit platelet platelet ␣-granules and was released from the granular aggregation.